1
|
Bousso A, Chuffart C, Leroy M, Gicquello A, Cottereau A, Hennegrave F, Beurnier A, Stoup T, Pereira S, Morelot-Panzini C, Taille C, Bautin N, Fry S, Perez T, Garcia G, Chenivesse C. Severity and phenotypes of dyspnea in asthma: Impact of comorbidities. Respir Med 2023:107276. [PMID: 37217082 DOI: 10.1016/j.rmed.2023.107276] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Revised: 04/13/2023] [Accepted: 05/04/2023] [Indexed: 05/24/2023]
Abstract
BACKGROUND Dyspnea is a common but non-specific symptom of asthma, which in particular may be related to anxiety and hyperventilation syndrome, two frequent comorbidities of asthma. METHODS We conducted a prospective multicentric cohort study in dyspneic asthmatic adults. Dyspnea was assessed using the Multidimensional Dyspnea Profile questionnaire. We described the sensory (QS) and affective (A2) domains of dyspnea and investigated the effect of poor asthma control, hyperventilation and anxiety on each dimension at baseline and after 6 months. RESULTS We included 142 patients (65.5% women, age: 52 years). Dyspnea was severe and predominated on its sensory domain (median QS: 27/50; A2: 15/50). Uncontrolled asthma (ACQ≥1.5), hyperventilation symptoms (Nijmegen≥23) and anxiety (HAD-A≥10) were present in 75%, 45.7% and 39% of cases, respectively. Hyperventilation symptoms were associated with higher QS and A2 scores: QS at 28.4(10.7) vs. 21.7(12.8) (p = 0.001) and A2 at 24(14) vs. 11.3(11) (p < 0.001) in patients with vs. without hyperventilation symptoms. Anxiety was only associated with increased A2 (27(12.3) vs. 10.9(11), p < 0.001). At 6 months, QS and A2 decreased of 7 and 3 points, respectively, in relation with changes in ACQ-6 and Nijmegen scores as well as the HAD-A score for A2. CONCLUSION In breathless asthmatics, dyspnea is severe and worsened but differentially modulated by hyperventilation symptoms and anxiety. A multidimensional phenotyping of dyspnea in asthmatics could be useful to understand its origins and personalize treatment.
Collapse
Affiliation(s)
- Awa Bousso
- Univ. Lille, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille, France
| | - Celine Chuffart
- Centre Hospitalier de Roubaix, Service de Pneumologie, Roubaix, France
| | - Maxime Leroy
- CHU Lille, Department of Biostatistics, F-59000, Lille, France
| | - Alice Gicquello
- Groupement des Hôpitaux de L'Institut Catholique de Lille, Service de Pneumologie, Lille, France
| | - Aurelie Cottereau
- Groupement des Hôpitaux de L'Institut Catholique de Lille, Service de Pneumologie, Lille, France
| | | | - Antoine Beurnier
- Bicêtre Hospital, Department of Physiology - Lung Function Testing, DMU 5 Thorinno, AP-HP - Paris Saclay University, Inserm UMR_S999, Le Kremlin Bicêtre, France; CRISALIS, F-CRIN Inserm Network, France
| | - Thomas Stoup
- Univ. Lille, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille, France
| | - Sophie Pereira
- Univ. Lille, CHU Lille, Service de Pneumologie et Immuno-Allergologie, Lille, France
| | - Capucine Morelot-Panzini
- GHU APHP-Sorbonne Université, Hôpital Pitié-Salpêtrière, Service de Pneumologie, Paris, France; UMRS 1158, Inserm-Sorbonne Université, Paris, France
| | - Camille Taille
- Bichat Hospital, Respiratory Diseases Department, Reference Center for Rare Pulmonary Diseases, AP-HP Nord - University of Paris Cité, Inserm 1152, 75018, Paris, France; UMRS 1158, Inserm-Sorbonne Université, Paris, France
| | - Nathalie Bautin
- UMRS 1158, Inserm-Sorbonne Université, Paris, France; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017- CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Stephanie Fry
- UMRS 1158, Inserm-Sorbonne Université, Paris, France; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017- CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Thierry Perez
- UMRS 1158, Inserm-Sorbonne Université, Paris, France; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017- CIIL - Center for Infection and Immunity of Lille, Lille, France
| | - Gilles Garcia
- Hopital Privé D'Antony, Service de Pneumologie, Antony, France
| | - Cecile Chenivesse
- UMRS 1158, Inserm-Sorbonne Université, Paris, France; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017- CIIL - Center for Infection and Immunity of Lille, Lille, France.
| |
Collapse
|
2
|
Guilleminault L, Camus C, Raherison-Semjen C, Capdepon A, Bourdin A, Bonniaud P, Fry S, Devouassoux G, Blanc FX, Pison C, Dupin C, Khayath N, Courdeau J, Valcke-Brossollet J, Nocent-Ejnaini C, Rolland F, Lamandi C, Proust A, Ozier A, Portel L, Gaspard W, Roux-Claude P, Beurnier A, Martinez S, Dot JM, Hennegrave F, Vignal G, Auvray E, Paleiron N, Just N, Miltgen J, Russier M, Olivier C, Taillé C, Didier A. Improvement in severe asthma patients receiving biologics and factors associated with persistent insufficient control: a real-life national study. Ther Adv Respir Dis 2023; 17:17534666231202749. [PMID: 37966015 PMCID: PMC10655663 DOI: 10.1177/17534666231202749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Accepted: 08/22/2023] [Indexed: 11/16/2023] Open
Abstract
BACKGROUND Biological therapies have revolutionized the treatment of severe asthma with type 2 inflammation. Although such treatments are very effective in reducing exacerbation and the dose of oral steroids, little is known about the persistence of symptoms in severe asthma patients treated with biologics. PURPOSE We aim to describe asthma control and healthcare consumption of severe asthma patients treated with biologics. DESIGN The Second Souffle study is a real-life prospective observational study endorsed by the Clinical Research Initiative in Severe Asthma: a Lever for Innovation & Science Network. METHODS Adults with a confirmed diagnosis of severe asthma for at least 12 months' duration were enrolled in the study. A self-administered questionnaire including the Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ) and a compliance evaluation test was given to the patients. Healthcare consumption within 12 months prior to enrolment was documented. In patients receiving biologics, doctors indicated whether the patients were biologic responders or non-responders. RESULTS The characteristics of 431 patients with severe asthma were analysed. Among them, 409 patients (94.9%) presented asthma with type 2 inflammation (T2 high) profile, and 297 (72.6%) patients with a T2 high phenotype were treated with a biologic. Physicians estimated that 88.2% of patients receiving biologics were responders. However, asthma control was only achieved in 25.3% of those patients (ACQ > 0.75). A high proportion of patients (77.8%) identified as responders to biologics were not controlled according to the ACQ score. About 50% of patients continue to use oral corticosteroids either daily (25.2%) or more than three times a year for at least three consecutive days (25.6%). Gastro-oesophageal Reflux Disease (GERD) and Obstructive Sleep Apnoea syndrome (OSA) were identified as independent factors associated with uncontrolled asthma. CONCLUSION Although a high proportion of severe asthma patients respond to biologics, only 25.3% have controlled asthma. GERD and OSA are independent factors of uncontrolled asthma.
Collapse
Affiliation(s)
- Laurent Guilleminault
- Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
| | - Claire Camus
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
| | - Chantal Raherison-Semjen
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- University of French West Indies, Respiratory Diseases Department, Pointe -à Pitre, Guadeloupe
| | | | - Arnaud Bourdin
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Montpellier University Hospital, Montpellier, France
| | - Philippe Bonniaud
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Dijon University Hospital, Dijon, France
| | - Stéphanie Fry
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Lille University Hospital, Lille, France
| | - Gilles Devouassoux
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Lyon University Hospital, HCL, Lyon, France
| | - François-Xavier Blanc
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Nantes Université, CHU de Nantes, INSERM, Service de Pneumologie, CIC 1413, l’Institut du Thorax, Nantes, France
| | - Christophe Pison
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Grenoble University Hospital, Grenoble, France
| | - Clairelyne Dupin
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Bichat Hospital, AP-HP, Paris, France
| | - Naji Khayath
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Strasbourg University Hospital, Strasbourg, France
| | - Joelle Courdeau
- Respiratory Diseases Department, Bigorre Hospital, Tarbes, France
| | | | | | - Fabien Rolland
- Respiratory Diseases Department, Cannes Hospital, Cannes, France
| | - Carmen Lamandi
- Respiratory Diseases Department, GHRMSA Hospital, Mulhouse, France
| | - Alain Proust
- Respiratory Diseases Department, Nimes Hospital, Nîmes, France
| | - Anaig Ozier
- Respiratory Diseases Department, Saint Augustin Clinic, Bordeaux, France
| | - Laurent Portel
- Respiratory Diseases Department, Libourne Hospital, Libourne, France
| | - Wanda Gaspard
- Respiratory Diseases Department, Army Training Hospital HIA Percy Clamart, Clamart, France
| | - Pauline Roux-Claude
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Jean Minjoz University Hospital, Besançon, France
| | - Antoine Beurnier
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Department of Physiology – Function Tests, DMU 5 Thorinno, twin-site Hôpital Bicêtre (Le Kremlin Bicêtre) and Ambroise Paré (Boulogne-Billancourt), AP-HP, Paris, France
| | - Stéphanie Martinez
- Respiratory Diseases Department, Aix-en-Provence Hospital, Aix-en-Provence, France
| | - Jean-Marc Dot
- Respiratory Diseases Department, Médipôle Hospital, Villeurbanne, France
| | | | | | - Etienne Auvray
- Respiratory Diseases Department, Métropole Savoie Hospital, Chambéry, France
| | - Nicolas Paleiron
- Respiratory Diseases Department, Army Training Hospital HIA Ste Anne Toulon, Toulon, France
| | - Nicolas Just
- Respiratory Diseases Department, Roubaix Hospital, Roubaix, France
| | - Jean Miltgen
- Respiratory Diseases Department, Polyclinique Les Fleurs, Ollioules, France
| | - Maud Russier
- Respiratory Diseases Department, Orléans Regional Hospital, Orléans, France
| | - Cécile Olivier
- Respiratory Diseases Department, La Louvière Private Hospital, Lille, France
| | - Camille Taillé
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
- Respiratory Diseases Department, Bichat Hospital, AP-HP, Paris, France
| | - Alain Didier
- Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital Centre, 24 chemin de Pouvourville, Toulouse 31059, France
- Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), Inserm U1291, University of Toulouse, CNRS U5282, Toulouse, France
- CRISALIS/F-CRIN INSERM Network, Toulouse, France
| |
Collapse
|
3
|
Koné B, Pérez‐Cruz M, Porte R, Hennegrave F, Carnoy C, Gosset P, Trottein F, Sirard J, Pichavant M, Gosset P. Boosting the IL-22 response using flagellin prevents bacterial infection in cigarette smoke-exposed mice. Clin Exp Immunol 2020; 201:171-186. [PMID: 32324274 PMCID: PMC7366752 DOI: 10.1111/cei.13445] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2019] [Revised: 03/27/2020] [Accepted: 04/10/2020] [Indexed: 12/29/2022] Open
Abstract
The progression of chronic obstructive pulmonary disease (COPD), a lung inflammatory disease being the fourth cause of death worldwide, is marked by acute exacerbations. These episodes are mainly caused by bacterial infections, frequently due to Streptococcus pneumoniae. This susceptibility to infection involves a defect in interleukin (IL)-22, which plays a pivotal role in mucosal defense mechanism. Administration of flagellin, a Toll-like receptor 5 (TLR-5) agonist, can protect mice and primates against respiratory infections in a non-pathological background. We hypothesized that TLR-5-mediated stimulation of innate immunity might improve the development of bacteria-induced exacerbations in a COPD context. Mice chronically exposed to cigarette smoke (CS), mimicking COPD symptoms, are infected with S. pneumoniae, and treated in a preventive and a delayed manner with flagellin. Both treatments induced a lower bacterial load in the lungs and blood, and strongly reduced the inflammation and lung lesions associated with the infection. This protection implicated an enhanced production of IL-22 and involved the recirculation of soluble factors secreted by spleen cells. This is also associated with higher levels of the S100A8 anti-microbial peptide in the lung. Furthermore, human mononuclear cells from non-smokers were able to respond to recombinant flagellin by increasing IL-22 production while active smoker cells do not, a defect associated with an altered IL-23 production. This study shows that stimulation of innate immunity by a TLR-5 ligand reduces CS-induced susceptibility to bacterial infection in mice, and should be considered in therapeutic strategies against COPD exacerbations.
Collapse
Affiliation(s)
- B. Koné
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - M. Pérez‐Cruz
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - R. Porte
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - F. Hennegrave
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - C. Carnoy
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - P. Gosset
- Service d’Anatomo‐pathologieHôpital Saint Vincent de PaulLilleFrance
| | - F. Trottein
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - J.‐C. Sirard
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - M. Pichavant
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| | - P. Gosset
- Université de LilleCNRSInsermCHU LilleInstitut Pasteur de LilleLilleFrance
| |
Collapse
|
4
|
Hennegrave F, Le Rouzic O, Fry S, Behal H, Chenivesse C, Wallaert B. Factors associated with daily life physical activity in patients with asthma. Health Sci Rep 2018; 1:e84. [PMID: 30623040 PMCID: PMC6266451 DOI: 10.1002/hsr2.84] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2018] [Revised: 07/09/2018] [Accepted: 07/20/2018] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND AND OBJECTIVES Little is known about the consequences of asthma on daily life physical activity (DLPA). The aim of this study was to evaluate DLPA and determine its relationship to clinical and functional parameters in patients with asthma. METHODS This was a single-center prospective study of DLPA conducted between May 2015 and June 2016 in northern France. Fifty-one adult patients with asthma and 36 healthy control subjects were enrolled. Four DLPA parameters were assessed for 5 consecutive days with a physical activity monitor: number of steps walked per day (SPD), total energy expenditure (EE, in kcal/day), EE spent in physical activity requiring ≥3 metabolic equivalents (METs), and time (min) spent in activities requiring ≥3 METs. Clinical characteristics, pulmonary function tests, 6-minute walk test, and four questionnaires (modified Medical Research Council [mMRC] for dyspnea, asthma control test [ACT], quality of life [AQLQ], and hospital anxiety and depression scale [HADS]), were evaluated. Comparisons of DLPA parameters between the two groups were performed using an analysis of covariance adjusted for age, sex, and body mass index (BMI). Relationships between DLPA parameters and patient characteristics were assessed in multivariable linear regression models. RESULTS Compared with patients with mild/moderate asthma, those with severe asthma had lower mean (± standard deviation) forced expiratory volume in 1 s (FEV1) (66 ± 24 vs 94 ± 15% predicted, P < 0.001), ACT score (16.7 ± 4.5 vs 19.8 ± 4.2, P = 0.015), and AQLQ score (157 ± 40 vs 184 ± 33, P = 0.012). There were no significant differences between the two groups in SPD (6560 ± 3915 vs 8546 ± 3431; adjusted P = 0.95), EE in physical activity requiring ≥3 METs (620 ± 360 vs 660 ± 140 kcal/day; P = 0.86), time spent in activities requiring EE ≥3 (120 ± 54 vs 121 ± 32 min/day; P = 0.69), or total EE (2606 ± 570 vs 2666 ± 551 kcal/day; P = 0.80). These four DLPA measures showed strong inter-parameter correlations in patients with asthma (r = 0.37-0.95, all P < 0.01). All four parameters were lower in the patients with asthma group than in the control group: SPD, 7651 ± 3755 vs 11704 ± 4054 (adjusted P < 0.001); EE in activities requiring ≥3 METs, 642 ± 360 vs 852 ± 374 kcal/day (adjusted P = 0.041); time spent in activities requiring ≥3 EE, 120 ± 73 vs 189 ± 85 min (adjusted P = 0.005); and total EE, 2639 ± 555 vs 2746 ± 449 kcal/day (adjusted P = 0.007). In the patients with asthma group, the number of SPD correlated with age, FEV1, mMRC score, 6-minute walk test distance, and HADS scores, but not with BMI or ACT test score. Using multivariate analysis, the number of SPD was associated with only age, anxiety, and FEV1, whereas total EE was associated with mMRC score and BMI. CONCLUSION Age, anxiety, and FEV1 were significantly associated with the number of SPD in patients with asthma. Addressing anxiety should be further studied as way to attempt to increase physical activity in patients with asthma.
Collapse
Affiliation(s)
- Florence Hennegrave
- Service de Pneumologie et ImmunoAllergologie, Centre de Référence constitutif des Maladies Pulmonaires Rares, Univ. LilleCHU Lille, Hopital CalmetteLilleFrance
| | - Olivier Le Rouzic
- Service de Pneumologie et ImmunoAllergologie, Centre de Référence constitutif des Maladies Pulmonaires Rares, Univ. LilleCHU Lille, Hopital CalmetteLilleFrance
| | - Stéphanie Fry
- Service de Pneumologie et ImmunoAllergologie, Centre de Référence constitutif des Maladies Pulmonaires Rares, Univ. LilleCHU Lille, Hopital CalmetteLilleFrance
| | - Hélène Behal
- Department of Biostatistics, Univ. Lille, EA 2694‐Santé Publique: Epidémiologie et Qualité des SoinsCHU LilleLilleFrance
| | - Cécile Chenivesse
- Service de Pneumologie et ImmunoAllergologie, Centre de Référence constitutif des Maladies Pulmonaires Rares, Univ. LilleCHU Lille, Hopital CalmetteLilleFrance
| | - Benoit Wallaert
- Service de Pneumologie et ImmunoAllergologie, Centre de Référence constitutif des Maladies Pulmonaires Rares, Univ. LilleCHU Lille, Hopital CalmetteLilleFrance
| |
Collapse
|
5
|
Le Rouzic O, Koné B, Kluza J, Marchetti P, Hennegrave F, Olivier C, Kervoaze G, Vilain E, Mordacq C, Just N, Perez T, Bautin N, Pichavant M, Gosset P. Cigarette smoke alters the ability of human dendritic cells to promote anti-Streptococcus pneumoniae Th17 response. Respir Res 2016; 17:94. [PMID: 27460220 PMCID: PMC4962368 DOI: 10.1186/s12931-016-0408-6] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 07/16/2016] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation and impaired immune response to pathogens leading to bacteria-induced exacerbation of the disease. A defect in Th17 cytokines in response to Streptococcus pneumoniae, a bacteria associated with COPD exacerbations, has been recently reported. Dendritic cells (DC) are professional antigen presenting cells that drive T-cells differentiation and activation. In this study, we hypothesized that exposure to cigarette smoke, the main risk factor of COPD, might altered the pro-Th17 response to S. pneumoniae in COPD patients and human DC. METHODS Pro-Th1 and -Th17 cytokine production by peripheral blood mononuclear cells (PBMC) from COPD patients was analyzed and compared to those from smokers and non-smokers healthy subjects. The effect of cigarette smoke extract (CSE) was analyzed on human monocyte-derived DC (MDDC) from controls exposed or not to S. pneumoniae. Bacteria endocytosis, maturation of MDDC and secretion of cytokines were assessed by flow cytometry and ELISA, respectively. Implication of the oxidative stress was analyzed by addition of antioxidants and mitochondria inhibitors. In parallel, MDDC were cocultured with autologous T-cells to analyze the consequence on Th1 and Th17 cytokine production. RESULTS PBMC from COPD patients exhibited defective production of IL-1β, IL-6, IL-12 and IL-23 to S. pneumoniae compared to healthy subjects and smokers. CSE significantly reduced S. pneumoniae-induced MDDC maturation, secretion of pro-Th1 and -Th17 cytokines and activation of Th1 and Th17 T-cell responses. CSE exposure was also associated with sustained CXCL8 secretion, bacteria endocytosis and mitochondrial oxidative stress. Antioxidants did not reverse these effects. Inhibitors of mitochondrial electron transport chain partly reproduced inhibition of S. pneumoniae-induced MDDC maturation but had no effect on cytokine secretion and T cell activation. CONCLUSIONS We observed a defective pro-Th1 and -Th17 response to bacteria in COPD patients. CSE exposure was associated with an inhibition of DC capacity to activate antigen specific T-cell response, an effect that seems to be not only related to oxidative stress. These results suggest that new therapeutics boosting this response in DC may be helpful to improve treatment of COPD exacerbations.
Collapse
Affiliation(s)
- Olivier Le Rouzic
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- CHU Lille, Service de Pneumologie Immunologie et Allergologie, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
| | - Bachirou Koné
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
| | - Jerome Kluza
- Univ. Lille, UMR-S 1172 – JPArc – Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
- Inserm, UMR-S 1172, F-59000 Lille, France
| | - Philippe Marchetti
- Univ. Lille, UMR-S 1172 – JPArc – Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer, F-59000 Lille, France
- Inserm, UMR-S 1172, F-59000 Lille, France
| | - Florence Hennegrave
- CHU Lille, Service de Pneumologie Immunologie et Allergologie, F-59000 Lille, France
| | - Cécile Olivier
- CHU Lille, Service de Pneumologie Immunologie et Allergologie, F-59000 Lille, France
| | - Gwenola Kervoaze
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
| | - Eva Vilain
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
| | - Clémence Mordacq
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
- CHU Lille, Service de Pédiatrie, F-59000 Lille, France
| | - Nicolas Just
- CH Roubaix, Service de Pneumologie, F-59100 Roubaix, France
| | - Thierry Perez
- CHU Lille, Service de Pneumologie Immunologie et Allergologie, F-59000 Lille, France
| | - Nathalie Bautin
- CHU Lille, Service de Pneumologie Immunologie et Allergologie, F-59000 Lille, France
| | - Muriel Pichavant
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
| | - Philippe Gosset
- Univ. Lille, U1019 – UMR 8204 – CIIL – Center for Infection and Immunity of Lille, F-59000 Lille, France
- CNRS, UMR 8204, F-59000 Lille, France
- Inserm, U1019, F-59000 Lille, France
- Institut Pasteur de Lille, F-59000 Lille, France
- LI3, CIIL - Institut Pasteur de Lille, F-59000 Lille, France
| |
Collapse
|
6
|
Hennegrave F. L’activité physique quotidienne est-elle impactée par le niveau de sévérité de l’asthme ? Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
7
|
Pichavant M, Sharan R, Le Rouzic O, Olivier C, Hennegrave F, Rémy G, Pérez-Cruz M, Koné B, Gosset P, Just N, Gosset P. IL-22 Defect During Streptococcus pneumoniae Infection Triggers Exacerbation of Chronic Obstructive Pulmonary Disease. EBioMedicine 2015; 2:1686-96. [PMID: 26870795 PMCID: PMC4740310 DOI: 10.1016/j.ebiom.2015.09.040] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Revised: 09/22/2015] [Accepted: 09/23/2015] [Indexed: 12/22/2022] Open
Abstract
Progression of chronic obstructive pulmonary disease (COPD) is linked to episodes of exacerbations caused by bacterial infections due to Streptococcus pneumoniae. Our objective was to identify during COPD, factors of susceptibility to bacterial infections among cytokine network and their role in COPD exacerbations. S. pneumoniae was used to sub-lethally challenge mice chronically exposed to air or cigarette smoke (CS) and to stimulate peripheral blood mononuclear cells (PBMC) from non-smokers, smokers and COPD patients. The immune response and the cytokine production were evaluated. Delayed clearance of the bacteria and stronger lung inflammation observed in infected CS-exposed mice were associated with an altered production of IL-17 and IL-22 by innate immune cells. This defect was related to a reduced production of IL-1β and IL-23 by antigen presenting cells. Importantly, supplementation with recombinant IL-22 restored bacterial clearance in CS-exposed mice and limited lung alteration. In contrast with non-smokers, blood NK and NKT cells from COPD patients failed to increase IL-17 and IL-22 levels in response to S. pneumoniae, in association with a defect in IL-1β and IL-23 secretion. This study identified IL-17 and IL-22 as susceptibility factors in COPD exacerbation. Therefore targeting such cytokines could represent a potent strategy to control COPD exacerbation.
Collapse
Key Words
- AM, alveolar macrophages
- APC, antigen presenting cells
- BAL, broncho-alveolar lavage
- Bacterial infection
- CFU, colony forming unit
- COPD, chronic obstructive pulmonary disease
- CS, cigarette smoke
- Chronic obstructive pulmonary disease
- DC, dendritic cells
- IL-22
- Innate immunity
- NK, natural killer cells
- NKT, natural killer T cells
- PBMC, peripheral blood mononuclear cells
- Sp, Streptococcus pneumoniae
Collapse
Affiliation(s)
- Muriel Pichavant
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Riti Sharan
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Olivier Le Rouzic
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Cécile Olivier
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Florence Hennegrave
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
- Service de Pneumologie, Hôpital Calmette, CHRU, Lille, France
| | - Gaëlle Rémy
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Magdiel Pérez-Cruz
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Bachirou Koné
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| | - Pierre Gosset
- Service d'Anatomo-Pathologie, Hôpital Saint Vincent de Paul, Lille, France
| | - Nicolas Just
- Service de Pneumologie, Hôpital Victor Provo, Roubaix, France
| | - Philippe Gosset
- Institut Pasteur de Lille, Centre d'Infection et d'Immunité de Lille, F-59019 Lille, France
- Université Lille Nord de France, F-59000 Lille, France
- Centre National de la Recherche Scientifique, UMR 8204, F-59021 Lille, France
- Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France
- Institut Fédératif de Recherche 142, F-59019 Lille, France
| |
Collapse
|
8
|
Hennegrave F, Just N, Le Rouzic O, Sirard J, Pichavant M, Gosset P. Capacité des immunostimulants à restaurer une réponse IL-17, IL-22, IFN-γ dans le cadre de la BPCO. Rev Mal Respir 2015. [DOI: 10.1016/j.rmr.2015.02.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|